Dr. Rousseau to lead clinical development as Pheast advances PHST001, a novel anti-CD24 macrophage checkpoint inhibitor, into ...
Dr. Rousseau to lead clinical development as Pheast advances PHST001, a novel anti-CD24 macrophage checkpoint inhibitor, into clinical trials Pheast Therapeutics, a private biotechnology company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback